Epidemiological considerations in the design of controlled clinical trials. Part II: Methodology

  • Bruce S. Schoenberg
  • Steven Haberman


Unlike the laboratory investigator who is able to manipulate experimental conditions precisely, the clinical epidemiologist studies disease and its treatment or prevention in humans who cannot be subjected to such rigid control available in the basic science laboratory. Special research strategies have therefore been designed to evaluate the efficacy of new treatments for diseases in humans. This report presents a brief review of the available methods, the rationale for their use, and the problems involved in their implementation, with particular reference to neurological diseases.


Control Clinical Trial Therapeutic Trial Motor Neurone Disease Transient Ischaemic Attack Aluminium Level 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Armitage, P. (1971). Statistical Methods in Medical Research. Blackwell Scientific Publications, Oxford.Google Scholar
  2. Clark, C. J. and Downie, C. C. (1966). A method for the rapid determination of the number of patients to include in a controlled clinical trial. Lancet, ii, 1357–8.CrossRefGoogle Scholar
  3. Cornfield, J. (1959). Principles of research. Am. J. Ment. Defic, 64, 240–52.Google Scholar
  4. Good, C. S. (1976). The Principles and Practice of Clinical Trials. Churchill Livingstone, London.Google Scholar
  5. Kurtzke, J. F. (1982). On the role of clinicians in the use of drug trial data. Neuroepidemiology, 1, 124–36.CrossRefGoogle Scholar
  6. Lilienfeld, A. M. and Lilienfeld, D. E. (1980). Foundations of Epidemiology. Oxford University Press, New York, pp. 256–74.Google Scholar
  7. Macrae, K. D. (1976). Statistical aspects of trial design. In Good, C. S. (ed.), The Principles and Practice of Clinical Trials. Churchill Livingstone, London, pp. 87–92.Google Scholar
  8. Schoenberg, B. S. (1978). Epidemiology of the inherited ataxias. In Kark, P., Rosenberg, R. and Schut, L. (eds), The Inherited Ataxias: Biochemical, Viral and Pathological Studies. Raven Press, New York, pp. 15–32.Google Scholar
  9. Schoenberg, B. S. (1979). The epidemiologic approach to Huntington’s disease. In Chase, T., Wexler, N. and Barbeau, A. (eds), Huntington’s Disease. Raven Press, New York, pp. 1–11.Google Scholar
  10. Schoenberg, B. S. (1982a). The scope of neuroepidemiology: from stone age to Stockholm. Neuroepidemiology, 1, 1–16.CrossRefGoogle Scholar
  11. Schoenberg, B. S. (1982b). Hypothesis testing in neuroepidemiology: experiments of nature and experiments of man. Neuroepidemiology, 1, 85–101.CrossRefGoogle Scholar
  12. Schoenberg, B. S. (1982c). Neuroepidemiologic definitions of disease: critiquing criteria. Neuroepidemiology, 1, 197–200.CrossRefGoogle Scholar

Copyright information

© The contributors 1988

Authors and Affiliations

  • Bruce S. Schoenberg
  • Steven Haberman

There are no affiliations available

Personalised recommendations